News

Vampire viruses prey on other viruses to replicate themselves

And they may hold the key to new antiviral therapies
Ivan Erill
By Ivan Erill
Nov. 18, 2023

Have you ever wondered whether the virus that gave you a nasty cold can catch one itself? It may comfort you to know that, yes, viruses can actually get sick. Even better, as karmic justice would have it, the culprits turn out to be other viruses.

Viruses can get sick in the sense that their normal function is impaired. When a virus enters a cell, it can either go dormant or start replicating right away. When replicating, the virus essentially commandeers the molecular factory of the cell to make lots of copies of itself, then breaks out of the cell to set the new copies free.

The satellite virus MiniFlayer (purple) infects cells by attaching itself to the neck of its helper virus, MindFlayer (gray).
The satellite virus MiniFlayer (purple) infects cells by attaching itself to the neck of its helper virus, MindFlayer (gray).

Sometimes a virus enters a cell only to find that its new temporary dwelling is already home to another dormant virus. Surprise, surprise. What follows is a battle for control of the cell that can be won by either party.

But sometimes a virus will enter a cell to find a particularly nasty shock: a viral tenant waiting specifically to prey on the incoming virus.

I am a bioinformatician, and my laboratory studies the evolution of viruses. We frequently run into “viruses of viruses,” but we recently discovered something new: a virus that latches onto the neck of another virus.

A world of satellites

Biologists have known of the existence of viruses that prey on other viruses — referred to as viral “satellites” — for decades. In 1973, researchers studying bacteriophage P2, a virus that infects the gut bacterium Escherichia coli, found that this infection sometimes led to two different types of viruses emerging from the cell: phage P2 and phage P4.

Bacteriophage P4 is a temperate virus, meaning it can integrate into the chromosome of its host cell and lie dormant. When P2 infects a cell already harboring P4, the latent P4 quickly wakes up and uses the genetic instructions of P2 to make hundreds of its own small viral particles. The unsuspecting P2 is lucky to replicate a few times, if at all. In this case, biologists refer to P2 as a “helper” virus, because the satellite P4 needs P2’s genetic material to replicate and spread.

Bacteriophages are viruses that infect bacteria.

Subsequent research has shown that most bacterial species have a diverse set of satellite-helper systems, like that of P4-P2. But viral satellites are not limited to bacteria. Shortly after the largest known virus, mimivirus, was discovered in 2003, scientists also found its satellite, which they named Sputnik. Plant viral satellites that lurk in plant cells waiting for other viruses are also widespread and can have important effects on crops.

Viral arms race

Although researchers have found satellite-helper viral systems in pretty much every domain of life, their importance to biology remains underappreciated. Most obviously, viral satellites have a direct impact on their “helper” viruses, typically maiming them but sometimes making them more efficient killers. Yet that is probably the least of their contributions to biology.

Satellites and their helpers are also engaged in an endless evolutionary arms race. Satellites evolve new ways to exploit helpers and helpers evolve countermeasures to block them. Because both sides are viruses, the results of this internecine war necessarily include something of interest to people: antivirals.

Recent work indicates that many antiviral systems thought to have evolved in bacteria, like the CRISPR–Cas9 molecular scissors used in gene editing, may have originated in phages and their satellites. Somewhat ironically, with their high turnover and mutation rates, helper viruses and their satellites turn out to be evolutionary hot spots for antiviral weaponry. Trying to outsmart each other, satellite and helper viruses have come up with an unparalleled array of antiviral systems for researchers to exploit.

MindFlayer and MiniFlayer

Viral satellites have the potential to transform how researchers understand antiviral strategies, but there is still a lot to learn about them. In our recent work, my collaborators and I describe a satellite bacteriophage completely unlike previously known satellites, one that has evolved a unique, spooky lifestyle.

Undergraduate phage hunters at the University of Maryland, Baltimore County, isolated a satellite phage called MiniFlayer from the soil bacterium Streptomyces scabiei. MiniFlayer was found in close association with a helper virus called bacteriophage MindFlayer that infects the Streptomyces bacterium. But further research revealed that MiniFlayer was no ordinary satellite.

This image shows Streptomyces satellite phage MiniFlayer (purple) attached to the neck of its helper virus, Streptomyces phage MindFlayer (gray).
This image shows Streptomyces satellite phage MiniFlayer (purple) attached to the neck of its helper virus, Streptomyces phage MindFlayer (gray).

MiniFlayer is the first satellite phage known to have lost its ability to lie dormant. Not being able to lie in wait for your helper to enter the cell poses an important challenge to a satellite phage. If you need another virus to replicate, how do you guarantee that it makes it into the cell around the same time you do?

MiniFlayer addressed this challenge with evolutionary aplomb and horror-movie creativity. Instead of lying in wait, MiniFlayer has gone on the offensive. Borrowing from both “Dracula” and “Alien,” this satellite phage evolved a short appendage that allows it to latch onto its helper’s neck like a vampire. Together, the unwary helper and its passenger travel in search of a new host, where the viral drama will unfold again. We don’t yet know how MiniFlayer subdues its helper, or whether MindFlayer has evolved countermeasures.

If the recent pandemic has taught us anything, it is that our supply of antivirals is rather limited. Research on the complex, intertwined and at times predatory nature of viruses and their satellites, like the ability of MiniFlayer to attach to its helper’s neck, has the potential to open new avenues for antiviral therapy.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Conversation

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ivan Erill
Ivan Erill

Ivan Erill is a professor of biological sciences at the University of Maryland, Baltimore County.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Omega-3 fats linked to healthy aging and improved heart metabolism
Journal News

Omega-3 fats linked to healthy aging and improved heart metabolism

Aug. 1, 2025

Scientists from the University of Iowa find that a diet high in polyunsaturated fatty acids from fish oil increases cardiac triglyceride uptake and improves insulin sensitivity. Read more about this recent JLR study.

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.